394 related articles for article (PubMed ID: 20402545)
21. Anti-chemokine small molecule drugs: a promising future?
Proudfoot AE; Power CA; Schwarz MK
Expert Opin Investig Drugs; 2010 Mar; 19(3):345-55. PubMed ID: 20113217
[TBL] [Abstract][Full Text] [Related]
22. Soluble epoxide hydrolase inhibitors: a patent review.
Shen HC
Expert Opin Ther Pat; 2010 Jul; 20(7):941-56. PubMed ID: 20429668
[TBL] [Abstract][Full Text] [Related]
23. Sodium channel blockers for neuropathic pain.
Zuliani V; Rivara M; Fantini M; Costantino G
Expert Opin Ther Pat; 2010 Jun; 20(6):755-79. PubMed ID: 20384535
[TBL] [Abstract][Full Text] [Related]
24. 5-HT(7) receptor modulators: a medicinal chemistry survey of recent patent literature (2004 - 2009).
Leopoldo M; Lacivita E; Berardi F; Perrone R
Expert Opin Ther Pat; 2010 Jun; 20(6):739-54. PubMed ID: 20476847
[TBL] [Abstract][Full Text] [Related]
25. Orexin receptor antagonists: a review of promising compounds patented since 2006.
Coleman PJ; Renger JJ
Expert Opin Ther Pat; 2010 Mar; 20(3):307-24. PubMed ID: 20180618
[TBL] [Abstract][Full Text] [Related]
26. Tricyclic covalent inhibitors selectively target Jak3 through an active site thiol.
Goedken ER; Argiriadi MA; Banach DL; Fiamengo BA; Foley SE; Frank KE; George JS; Harris CM; Hobson AD; Ihle DC; Marcotte D; Merta PJ; Michalak ME; Murdock SE; Tomlinson MJ; Voss JW
J Biol Chem; 2015 Feb; 290(8):4573-4589. PubMed ID: 25552479
[TBL] [Abstract][Full Text] [Related]
27. Synthetic staurosporines via a ring closing metathesis strategy as potent JAK3 inhibitors and modulators of allergic responses.
Wilson LJ; Malaviya R; Yang C; Argentieri R; Wang B; Chen X; Murray WV; Cavender D
Bioorg Med Chem Lett; 2009 Jun; 19(12):3333-8. PubMed ID: 19427203
[TBL] [Abstract][Full Text] [Related]
28. Selective inhibitors of the Janus kinase Jak3--Are they effective?
Thoma G; Drückes P; Zerwes HG
Bioorg Med Chem Lett; 2014 Oct; 24(19):4617-4621. PubMed ID: 25217444
[TBL] [Abstract][Full Text] [Related]
29. Chemoprevention of colorectal cancer by targeting Janus kinase 3 with a rationally designed small molecule inhibitor.
Uckun FM; Dibirdik I
Nutr Cancer; 2010; 62(7):968-72. PubMed ID: 20924972
[TBL] [Abstract][Full Text] [Related]
30. Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.
Kettle JG; Åstrand A; Catley M; Grimster NP; Nilsson M; Su Q; Woessner R
Expert Opin Ther Pat; 2017 Feb; 27(2):145-161. PubMed ID: 27774822
[TBL] [Abstract][Full Text] [Related]
31. Small-molecule pan-IAP antagonists: a patent review.
Flygare JA; Fairbrother WJ
Expert Opin Ther Pat; 2010 Feb; 20(2):251-67. PubMed ID: 20100005
[TBL] [Abstract][Full Text] [Related]
32. Inhibitors of diacylglycerol acyltransferase: a review of 2008 patents.
King AJ; Judd AS; Souers AJ
Expert Opin Ther Pat; 2010 Jan; 20(1):19-29. PubMed ID: 20021283
[TBL] [Abstract][Full Text] [Related]
33. Diamino-1,2,4-triazole derivatives are selective inhibitors of TYK2 and JAK1 over JAK2 and JAK3.
Malerich JP; Lam JS; Hart B; Fine RM; Klebansky B; Tanga MJ; D'Andrea A
Bioorg Med Chem Lett; 2010 Dec; 20(24):7454-7. PubMed ID: 21106455
[TBL] [Abstract][Full Text] [Related]
34. Recent advances in irreversible kinase inhibitors.
Gilbert AM
Pharm Pat Anal; 2014 Jul; 3(4):375-86. PubMed ID: 25291312
[TBL] [Abstract][Full Text] [Related]
35. Thrombin receptors and their antagonists: an update on the patent literature.
Cirino G; Severino B
Expert Opin Ther Pat; 2010 Jul; 20(7):875-84. PubMed ID: 20450349
[TBL] [Abstract][Full Text] [Related]
36. Cyclin-dependent kinase inhibitors: a survey of recent patent literature.
Galons H; Oumata N; Meijer L
Expert Opin Ther Pat; 2010 Mar; 20(3):377-404. PubMed ID: 20180621
[TBL] [Abstract][Full Text] [Related]
37. Focusing on new monoamine oxidase inhibitors.
Bolasco A; Carradori S; Fioravanti R
Expert Opin Ther Pat; 2010 Jul; 20(7):909-39. PubMed ID: 20553094
[TBL] [Abstract][Full Text] [Related]
38. New patented histone deacetylase inhibitors.
Wang H; Dymock BW
Expert Opin Ther Pat; 2009 Dec; 19(12):1727-57. PubMed ID: 19939190
[TBL] [Abstract][Full Text] [Related]
39. Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer.
Edwards J
Expert Opin Investig Drugs; 2010 May; 19(5):605-14. PubMed ID: 20367532
[TBL] [Abstract][Full Text] [Related]
40. Review of recent acetyl-CoA carboxylase inhibitor patents: mid-2007-2008.
Corbett JW
Expert Opin Ther Pat; 2009 Jul; 19(7):943-56. PubMed ID: 19552511
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
